CD274 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC) (the most common lung cancer subtype), PD-1 and PD-L1 inhibitors are increasingly being used, and do improve survival in comparison to traditional chemotherapies (214, 215).